1. Identification of leads for antiproliferative activity on MDA-MB-435 human breast cancer cells through pharmacophore and CYP1A1-mediated metabolism.
- Author
-
Nandekar PP, Khomane K, Chaudhary V, Rathod VP, Borkar RM, Bhandi MM, Srinivas R, Sangamwar AT, Guchhait SK, and Bansal AK
- Subjects
- Antineoplastic Agents chemical synthesis, Antineoplastic Agents chemistry, Breast Neoplasms drug therapy, Cell Line, Tumor, Cell Proliferation drug effects, Cytochrome P-450 CYP1A1 metabolism, Dose-Response Relationship, Drug, Drug Screening Assays, Antitumor, Female, Humans, Indoles chemical synthesis, Indoles chemistry, Molecular Structure, Structure-Activity Relationship, Antineoplastic Agents pharmacology, Breast Neoplasms metabolism, Breast Neoplasms pathology, Cytochrome P-450 CYP1A1 antagonists & inhibitors, Indoles pharmacology
- Abstract
CYP1A1 is a potential target for anticancer drug development due to its overexpression in certain cancer cells and role in cancer progression. To identify new leads for CYP1A1 mediated anticancer action, we attempted ligand based pharmacophore mapping, virtual screening of databases, molecular docking, MetaSite based filtering, and molecular dynamics simulations. Initial computational and in vitro screening identified 11 compounds from which we identified two lead compounds, ZINC33468944 and ZINC32101539, showed potential antitumor activity on MDA-MB-435 cell lines (GI50 < 0.1 μM) and CYP1A1 inhibition of 0.13 and 0.3 μM, respectively. Furthermore, the lead compounds were evaluated for CYP1A1 mediated metabolism, showing N-hydroxylated metabolites, which have potential of DNA adduct formation and cause cancerous cell death. Analysis of molecular dynamics simulations provided important guidelines for the further modification of the lead compounds. Hence, we claim the lead molecules for further development in anticancer drug discovery., (Copyright © 2016 Elsevier Masson SAS. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF